Triple negative breast cancer affects 15% of patients each year in France. It tends to affect younger women than usual with breast cancer and it remains difficult to treat. But encouraging results have just been published in the New England Journal of Medicineaccording to a study presented at the European Congress of Oncology in Barcelona.
The aim of this study was to‘Integrating immunotherapy into triple negative treatment from the start’. Until now, immunotherapy was only combined with chemotherapy at a certain stage of the cancer. In this case, pembrolizumab was tested. The doctors aimed to avoid relapses and the development of metastatic forms. To date, nearly 7,000 patients have already benefited from this combination of treatments.
Very satisfactory survival rate
And this test proved conclusive, because the researchers noticed that the risk of death at 5 years had reduced by 34%The survival rate has risen to 86.6%, says Marie-Ange Mouret-Reynier, an oncologist at the Clermont-Ferrand Cancer Center and one of the authors of the study. She points out that the percentage of patients who relapse is low and the majority are cured.
Other studies around immunotherapy and triple negative breast cancer are underway to date, as revealed by the Curie Institute in April 2024. This is the case of “Skyline”, within the framework of the RHU CASSIOPEIA Future Investment Program. “It aims to evaluate the effectiveness of a new combination of two immunotherapies in association with chemotherapy in women with triple-negative breast cancer and to better visualize the cancer and its possible metastases thanks to innovative imaging used for the first time in France.”
Source: www.topsante.com
